# Progress Note 03 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Satchel Paige (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML047-SYN
- Date: 2026-09-08
- Fictional facility: St. Posthumous Health Center
- Fictional author: Delphine Whitaker-Osei, MD
- Calendar frame: modern shifted

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Eight-week review: the new inhaler, rehabilitation, the screening CT and lipids. **S**

## History of present illness

Mr. Paige returns six weeks after starting umeclidinium-vilanterol and eight weeks after starting atorvastatin. He takes the inhaler every morning and has not missed a dose; he has no dry mouth or trouble passing urine. He can now walk to the store without stopping, and uses albuterol two or three times a week. He has been to eight rehabilitation sessions and walks on the days between. He has had no flare-up. His low-dose CT five weeks ago showed emphysema in the upper lobes, a 4 mm nodule with a benign appearance, and calcium in the coronary arteries; he has no chest pain on exertion. He has had no muscle aches on atorvastatin. **S**

| Element | Detail |
|---|---|
| Symptoms | CAT 14, from 18; mMRC 1 |
| Reliever use | Two or three times a week |
| Low-dose CT | Centrilobular emphysema; 4 mm nodule, Lung-RADS 2; moderate coronary calcification |
| Lipids | LDL 86 mg/dL, from 148 |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Respiratory | Positive | Less breathless; little morning sputum; no wheeze |
| Cardiovascular | Negative | No chest pain, pressure or palpitations on exertion; no ankle swelling |
| Genitourinary | Negative | No hesitancy or poor stream |
| Musculoskeletal | Negative | No muscle aches |

4 systems reviewed. **S**

## Current medications

- Albuterol 90 micrograms per inhalation metered-dose inhaler with a spacer, two inhalations every four hours as needed for breathlessness **S**
- Umeclidinium 62.5 micrograms with vilanterol 25 micrograms dry powder inhaler (a LAMA with a LABA), one inhalation once a day **S**
- Atorvastatin 20 mg tablet once a day **S**

## Allergies

- No known allergy **S**

## Objective

BP 130/78 mmHg; pulse 78 bpm; respirations 16/min; temperature 36.6 °C; oxygen saturation 95% on room air; weight 82.8 kg; BMI 22.7 kg/m². All vital signs are synthetic.

Total cholesterol: 158 mg/dL; HDL cholesterol: 46 mg/dL; LDL cholesterol (calculated): 86 mg/dL; Triglycerides: 130 mg/dL. All results are synthetic.

## Change since baseline

- Total cholesterol: 224 mg/dL (high) at baseline, 158 mg/dL at this visit **S**
- HDL cholesterol: 44 mg/dL at baseline, 46 mg/dL at this visit **S**
- LDL cholesterol (calculated): 148 mg/dL (high) at baseline, 86 mg/dL at this visit **S**
- Triglycerides: 160 mg/dL (high) at baseline, 130 mg/dL at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| General | Comfortable; blood pressure 130/78, pulse 78, oxygen saturation 95 percent on room air |
| Respiratory | Reduced breath sounds; no wheeze or crackles |
| Cardiovascular | Regular rhythm; no edema |
| Inhaler technique | Dry powder inhaler used correctly with a strong, deep breath in and a breath-hold |

All examination findings are synthetic. **S**

## Assessment and plan

1. **COPD, GOLD grade 2, group B** (J44.9). Clear benefit from the LAMA with LABA and from rehabilitation: CAT 18 to 14 and mMRC 2 to 1, with less reliever use. The CT confirms centrilobular emphysema. The 4 mm nodule is benign in appearance (Lung-RADS 2). **S**
   - Continue umeclidinium-vilanterol and rehabilitation.
   - Next low-dose CT in twelve months.
2. **Hyperlipidemia on atorvastatin** (E78.5). LDL down from 148 to 86 mg/dL without side effects. Coronary calcification on the CT supports continuing the statin. **S**
   - Continue atorvastatin 20 mg; lipid panel yearly.
   - Report any chest pain on exertion at once.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Survey | Symptoms: CAT and mMRC dyspnea scale | Every visit | Completed today | CAT 14; mMRC 1 |
| Survey | Exacerbations in the past 12 months (moderate and severe) and GOLD group | Every visit | Completed today | None; group B |
| Examination | Pulse oximetry at rest | Every visit | Completed today | 95 percent on room air |
| Laboratory | Spirometry: post-bronchodilator FEV1/FVC and FEV1 % predicted (race-neutral GLI Global) | At diagnosis, then at least yearly or with a clear change | Up to date | Diagnostic spirometry six weeks ago; repeat in a year |
| Self-management | Smoking status and cessation support | Every visit | Completed today | Smoke-free |
| Examination | BMI and nutrition | Every visit | Completed today | BMI 22.7 |
| Medication safety | Inhaler technique, adherence and side effects (dry mouth, urinary retention) | Every visit | Completed today | Correct technique; no missed doses; no dry mouth or urinary symptoms |
| Imaging | Low-dose CT lung cancer screening | Yearly at 50 to 80 with 20 or more pack-years, while within fifteen years of quitting | Completed today | Done five weeks ago: Lung-RADS 2 (4 mm solid nodule); emphysema; coronary calcification; next in twelve months |
| Referral | Pulmonary rehabilitation | Offer when mMRC is 2 or more, or CAT 10 or more; within three weeks of a hospital discharge for an exacerbation | Completed today | Eight of twenty sessions completed |
| Laboratory | Lipid panel after starting a statin | Four to twelve weeks after starting, then yearly | Completed today | Total cholesterol 158, HDL 46, LDL 86, triglycerides 130 mg/dL |
| Medication safety | Statin safety: muscle symptoms | Every visit | Completed today | No muscle aches |
| Examination | ECG and cardiovascular risk | At baseline; reassess after exacerbations | Up to date | Normal ECG at intake; coronary calcification noted on CT; no angina |
| Self-management | Vaccines: influenza, pneumococcal, RSV, COVID-19, Tdap, zoster | Yearly review | Due | Influenza, RSV, COVID-19 and zoster at the wellness visit in four weeks |
| Examination | Long-term oxygen assessment | When resting PaO2 is 55 mm Hg or less (60 with cor pulmonale or polycythemia) or saturation 88 percent or less, confirmed twice | Not indicated | Saturation 95 percent; no change since the blood gas |

## Goal progress

- Find the cause of the breathlessness. Outcome by 2026-07-28: COPD confirmed by spirometry (post-bronchodilator FEV1/FVC 0.58); heart failure unlikely (NT-proBNP 92, normal ECG); alpha-1 antitrypsin normal. **S**
- Walk farther with less breathlessness. In progress; target 2026-10-27. **S**
- Fewer and milder flare-ups, treated early. In progress; target 2027-07-14. **S**
- LDL below 100 mg/dL. Outcome by 2026-09-08: LDL 148 to 86 mg/dL on atorvastatin 20 mg. **S**
- Vaccines up to date. In progress; target 2026-10-06. **S**

## Guideline basis

- Global Strategy for the Prevention, Diagnosis and Management of COPD: 2025 Report (2025), Global Initiative for Chronic Obstructive Lung Disease
- Race and Ethnicity in Pulmonary Function Test Interpretation: An Official American Thoracic Society Statement (2023), American Thoracic Society (American Journal of Respiratory and Critical Care Medicine 2023;207(8):978-995)
- CMID: Clinical Monitoring Intelligence Database, COPD and hyperlipidemia monographs (2026), Aether Forge
- Pulmonary Rehabilitation for Adults with Chronic Respiratory Disease: An Official American Thoracic Society Clinical Practice Guideline (2023), American Thoracic Society (American Journal of Respiratory and Critical Care Medicine 2023;208(4):e7-e26)
- Home Oxygen Therapy for Adults with Chronic Lung Disease: An Official American Thoracic Society Clinical Practice Guideline (2020), American Thoracic Society (American Journal of Respiratory and Critical Care Medicine 2020;202(10):e121-e141)
- A Randomized Trial of Long-Term Oxygen for COPD with Moderate Desaturation (LOTT) (2016), Long-Term Oxygen Treatment Trial Research Group (New England Journal of Medicine 2016;375(17):1617-1627)
- Racial Bias in Pulse Oximetry Measurement (2020), Sjoding MW, et al. (New England Journal of Medicine 2020;383(25):2477-2478)
- Lung Cancer: Screening (2021), U.S. Preventive Services Task Force
- Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: Preventive Medication (2022), U.S. Preventive Services Task Force
- Adult Immunization Schedule by Age (2026), Centers for Disease Control and Prevention

## Follow-up

- Wellness visit with vaccines in four weeks. Fifteen-week review in seven weeks. **S**
- Next scheduled visit 2026-10-06: subsequent annual wellness visit. **S**
